Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) — Dapa-Stress  

Type 1 Diabetes Clinical Trial

Official title: A Randomized, Double-Blinded, Placebo-controlled, Single-center Phase 1 Pilot Study to Explore the Effect of DAPAglifozin and Stress ( i.v. ACTH) on the Development of DKA After Insulin Withdrawal in Adolescent and Adult Subjects With T1D

Status Terminated

Clinical Trial Summary

Type 1 Diabetes is characterized by an absolute lack of insulin caused by autoimmune ß-cell destruction. Looking for different therapeutic approaches, beyond the administration of Insulin SGLT-Inhibitors (SGLT=sodium-glucose cotransporter) like Dapagliflozin look like a promising option to avoid hyperglycaemic excursions which are a reason for glycaemic variability by renal excretion of excessive glucose without administration of extra insulin. But also euglycemic DKA has been reported during SGLT2 add-on therapy to insulin in T1D and mechanistic studies have been called for.

The role of Dapagliflozin-induced hyperglucagonemia and stress/infection precipitating euglycemic DKA in this situation is unclear.

Thus the purpose of this pilot study is to collect clinical data on the development of DKA after insulin-withdrawal with Dapagliflozin compared to placebo and the added effect of a single dose of 4mg/kg i.v. ACTH as mediator of stress.

The first objective is to investigate the time to DKA (defined as Bicarbonate <19 mmol/l) after insulin withdrawal during treatment with a stable 5 day single daily dose of 10mg Dapagliflozin in patients with type 1 Diabetes.

In addition it should be evaluate the additional effect of stress, modelled by a single injection of ACTH on DKA development during Dapagliflozin Treatment.

We also want to know if Dapagliflozin influences glucagon levels during insulin withdrawal and how this is associated with the time course of DKA development.

Clinical Trial Description

The purpose of the Dapastress trial is, to evaluate if some metabolic parameters can be identified as an early marker or contributor in development of ketonic metabolic imbalance. As the hormonal "background" is completely different in pubertal adolescents compared to adults (especially contra-insulin hormones as growth hormone, glucagon).

Approximately 20 subjects 18-45 years will be screened in order to randomize 16 patients, where stress and Dapagliflozin (or corresponding placebo) will be administered independently.

The trial will consist of 14 visits: a screening visit (Visit 1), 4 overnight visits complexes (Visit 2 to Visit 13), including phone visits and a follow-up visit (Visit 14). Furthermore, an information visit will take place prior to the screening visit in order to obtain patient's informed consent. Screening will take place 2-21 days prior to Visit 2. The follow-up visit will take place 5-21 days after the end of Visit 13. The overnight visits will be separated by a wash-out period (5-30 days between the end of each visit complex and start of next complex) during which the subjects will resume their normal insulin treatment. Each phone visit will take place 3-5 days after the end of overnight Visits.

The planned total duration of the trial is 58-100 days per subject (rescheduled visits excluded). Each subject will be randomised to a unique treatment sequence (1:1:1:1).

Seq 1: A D B C Seq 2: B A C D Seq 3: C B D A Seq 4: D C A B (e.g. A Dapa-Stress, B Dapa-Placebo Stress , C Placebo- Stress, D Placebo-Placebo Stress)

After randomization patients will receive Dapagliflozin/placebo for 5 single daily Dosis. During the overnight visits the metabolic control will be achieved by a variable i.v. Infusion of human Insulin by an Infusion pump. The procedure will be used in order to aim and maintain blood glucose levels between 70 and 180 mg/dl. The fluid Infusion and Insulin dosing scheme will depend on Body weight and blood glucose levels. At approximately 03:00 hours in the morning the blood glucose should be within target range. Then insulin infusion will be suspended. In the morning the last dose of actual study medication (Dapagliflozin/ Placebo) and the single dose of stress (ACTH or placebo) will be administered. During now started stress phase blood samples for determination of metabolic Panels,blood gas analysis, Glucose and ketone will be taken hourly and vital signs tested. 12 hours after administration of stress (ACTH or placebo) the patients will resume their CSII and will be discharged when being well on investigator's judgement. ;

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Diabetic Ketoacidosis
• Ketosis
• Type 1 Diabetes

• NCT number: NCT04234867
• Study type: Interventional
• Source: Kinderkrankenhaus auf der Bult
• Status: Terminated
• Phase: Phase 1
• Start date: May 18, 2022
• Completion date: August 26, 2022